Pell Bio-Med Technology Co., Ltd. (6949.TW)
Taiwan · TWD · Healthcare · Biotechnology
NT$39.55 (+4.91%) as of
Key statistics
- Market cap
- 51.85B
- EPS (TTM)
- -0.36
- Dividend yield
- 0.00%
- 52-week range
- 34.75 – 1,490.00
- Beta
- 1.33
- Revenue (TTM)
- 28.93M
- Profit margin
- 0.00%
- Volume
- 3.66M
About Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-modified immune cell therapy. The company was founded in 2017 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.